Denali therapeutics announces topline results for regimen g evaluating eif2b agonist dnl343 in the phase 2/3 healey als platform trial

South san francisco, calif., jan. 06, 2025 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli) today announced topline results from an analysis of regimen g of the phase 2/3 healey als platform trial evaluating eif2b agonist dnl343 in the treatment of amyotrophic lateral sclerosis (als).
DNLI Ratings Summary
DNLI Quant Ranking